Cipla gets EIR from USFDA for Goa facility
Pharma major Cipla Thursday said it has received an establishment inspection report (EIR) from the US health regulator after inspection of its Goa facility. The United States Food and Drug Administration (USFDA) had inspected the Goa manufacturing facility from January 21-28, 2019, Cipla said in a filing to BSE.
Thereafter, the company received an EIR, indicating closure of the inspection, it added. Shares of Cipla closed at Rs 522.10 per scrip on BSE, up 0.37 per cent from the previous close.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
Advertisement
ALSO READ
ECI provides facility of home voting for elderly and PwDs in 2024 Lok Sabha elections
New Delhi: Radiation therapy facility started in Lady Hardinge Hospital
Varun Beverages starts commercial production of carbonated drinks at Gorakhpur facility
Mark Patterson reopens world’s largest wool processing facility
SGS Automotive Testing Facility in Chakan, Pune Receives Gold Rating from Indian Green Building Council